Get the latest news, insights, and market updates on ADPT (Adaptive Biotechnologies Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and attribution analysis. A copy of the letter can be downloaded here. In the quarter, the US equity market rallied, with the S&P 500 Index reaching 8.12%. Bonds also finished higher in […] Nov 17, 2025 - $ADPT
Adaptive Biotechnologies (ADPT) Surges to First Profit and Lifts Guidance—Has the Investment Case Evolved?
Adaptive Biotechnologies reported third quarter 2025 results, posting sales of US$93.97 million and net income of US$9.55 million, reversing a net loss from the same period last year, and raised its full-year revenue guidance for the MRD business to US$202–207 million. This marked the company’s first profitable quarter while also posting nearly double the prior year’s sales for the period, reflecting meaningful operational momentum. We'll examine how Adaptive Biotechnologies' return to... Nov 7, 2025 - $ADPT
Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Nov 6, 2025 - $ADPT
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UKPresentation on Wednesday, November 19, 2025, at 8:00 a.m. Greenwich Mean Time Piper Sandler 37th Annual Health Nov 6, 2025 - $ADPT
Adaptive Biotechnologies: Q3 Earnings Snapshot
The Seattle-based company said it had profit of 6 cents per share. Losses, adjusted for non-recurring gains, came to 15 cents per share. The results surpassed Wall Street expectations. Nov 5, 2025 - $ADPT
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2025. “Our third quarter results reflect another period of strong growth and financial progress,” said Chad Robins, chief executive officer and c Nov 5, 2025 - $ADPT
How New Developments Are Shaping Analyst Views on Adaptive Biotechnologies’ Future
Adaptive Biotechnologies has seen its fair value estimate climb from $16.00 to $17.14 per share, reflecting a moderate revision upward by market analysts. This change comes as experts weigh Adaptive’s strong standing in cancer diagnostics as well as the company’s potential to sustain growth within its core minimal residual disease (MRD) testing market. Stay tuned to discover how investors can navigate these narrative shifts and keep informed on future developments. Stay updated as the Fair... Nov 2, 2025 - $ADPT
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple